

AGENDA

**Uniform Formulary Beneficiary Advisory Panel
9 January 2014 @ 0900 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting : (BAP members only @ 8:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drug classes during the November 2013 meeting and December 2013 interim meeting:

- **Designated Newly Approved Drugs**
 - *Dipeptidyl Peptidase-4 (DPP-4) inhibitors – Alogliptin (Nesina), alogliptin/metformin (Kazano), alogliptin/pioglitazone (Oseni)*
 - *Osteoporosis Drugs - Bisphosphonates – Alendronate effervescent tablets (Binosto)*
- **Drug Class Reviews:**
 - *Short-Acting Beta Agonists (SABAs) metered dose inhalers*
 - *Benign Prostatic Hyperplasia (BPH) Drugs- 5-Alpha Reductase Inhibitors (5-ARIs)*
 - *Antilipidemic-Is (LIP-Is)*
- **Utilization Management Issues**
 - **Prior Authorization Criteria**
 - *Dimethyl Fumarate (Tecfidera)*
 - **Targeted Immunomodulatory Biologics (TIBs):**
 - *Certolizumab (Cimzia)*
 - *Tocilizumab (Actemra)*
 - *Ustekinumab (Stelara)*
 - *Montelukast (Singulair) - PA Removal*

➤ *2008 Section 703 Actions*

➤ **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.